MENLO PARK, Calif., Feb. 27, 2023 /PRNewswire/ -- PacBio (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing solutions, announced today that it will be participating in Cowen's 43rd Annual Health Care Conference in Boston, Massachusetts.
PacBio management is scheduled to participate in a fireside chat on Tuesday, March 7th at 12:50 PM ET. Interested parties may access a live and archived webcast of the event at the company's investors page at investor.pacificbiosciences.com.
About PacBio
Pacific Biosciences of California, Inc. (NASDAQ: PACB) is a premier life science technology company that is designing, developing and manufacturing advanced sequencing solutions to help scientists and clinical researchers resolve genetically complex problems. Our products and technology under development stem from two highly differentiated core technologies focused on accuracy, quality and completeness which include our existing HiFi long read sequencing and our emerging SBB™ short read sequencing technologies. Our products address solutions across a broad set of research applications including human germline sequencing, plant and animal sciences, infectious disease and microbiology, oncology, and other emerging applications. For more information, please visit www.pacb.com and follow @PacBio.
Contacts
Investors:
Todd Friedman
650.521.8450
This email address is being protected from spambots. You need JavaScript enabled to view it.
Media:
Lizelda Lopez
This email address is being protected from spambots. You need JavaScript enabled to view it.
Last Trade: | US$1.53 |
Daily Change: | 0.02 1.32 |
Daily Volume: | 7,127,971 |
Market Cap: | US$459.570M |
October 08, 2025 October 07, 2025 September 22, 2025 September 03, 2025 August 07, 2025 |
Terns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...
CLICK TO LEARN MOREChimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MOREEnd of content
No more pages to load